We demonstrated that hot spot activating PIK3CA and KRAS/HRAS mutations were associated with poor PFS among HNSCC patients treated with cetuximab in the first-line recurrent setting, but not among patients treated with cetuximab in combination with radiotherapy. Here, KRAS is linked to head and neck squamous cell carcinoma.